Price$27.86+1.27 (+4.78%)
03:15 PM06:45 PM
News · 26 weeks47-55%
2025-12-142026-06-07
Mix2990d
- SEC Filings10(34%)
- Other9(31%)
- Insider8(28%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- SECNeurogene Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Neurogene Inc. (0001404644) (Filer)
- PRNeurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett SyndromeExceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to strong demand from Rett syndrome community NGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026 Topline data from Embolden anticipated in 2H 2027 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the successful completion of dosing in the Embolden™ registrational trial of NGN-401, an investigational gene therapy designed to be a potential best-in-class, one-time treatment fo
- SECNeurogene Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Neurogene Inc. (0001404644) (Filer)
- ANALYSTRodman & Renshaw initiated coverage on Neurogene with a new price targetRodman & Renshaw initiated coverage of Neurogene with a rating of Buy and set a new price target of $70.00
- PRNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 17,045 shares of the Company's common stock to two new employees (the "Inducement Grants") on June 1, 2026 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listi
- SECNeurogene Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Neurogene Inc. (0001404644) (Filer)
- SECSEC Form 10-Q filed by Neurogene Inc.10-Q - Neurogene Inc. (0001404644) (Filer)
- PRNeurogene Reports First Quarter 2026 Financial Results and Highlights Recent UpdatesDosed ~90% of participants in Embolden™ registrational trial of NGN-401 for Rett syndrome; on track to complete dosing in the second quarter of 2026 NGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026 Presentation at ASGCT Meeting highlighted therapeutic rationale for ICV delivery in CNS-targeted gene therapy, including NGN-401 Strong cash position provides runway through first quarter of 2028 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2026 finan
- PRNeurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene TherapyICV is a commonly used neurosurgical procedure performed across multiple therapeutic settings, including gene therapy Presentation adds to body of evidence that ICV administration results in broad biodistribution of gene therapy to the brain and nervous system Use of ICV administration in NGN-401 gene therapy program for Rett syndrome provides potential rationale for the multidomain and durable improvements observed in Phase 1/2 trial Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, highlighted data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meet
- INSIDERPresident and CFO Cvijic Christine Mikail sold $300,043 worth of shares (9,600 units at $31.25) as part of a pre-agreed trading plan (SEC Form 4)4 - Neurogene Inc. (0001404644) (Issuer)
- INSIDERSEC Form 4 filed by Chief Commercial Officer Shafer Christina4 - Neurogene Inc. (0001404644) (Issuer)
- PRNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 122,565 shares of the Company's common stock to two new employees (the "Inducement Grants") on May 5, 2026 (the "Grant Date"), including an Inducement Grant with respect to 120,000 shares issued to the Company's new Chief Commercial Officer, Christy Shafer, with a vesting commencement date of April 20, 2026, the date of Ms. Shafer's hire. The Inducement Grants have
- PRNeurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene TherapyPresentation at ASGCT Meeting will feature ICV as a routine neurosurgical procedure that provides broad biodistribution of gene therapy to the brain and nervous system Safety and efficacy of NGN-401 for Rett syndrome, delivered via ICV administration, to be highlighted Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an upcoming poster presentation that will demystify the intracerebroventricular (ICV) route of administration as a well-established, routinely performed neurosurgical procedure and a deliberate delivery strategy designed to maximize efficac
- INSIDERSEC Form 3 filed by new insider Shafer Christina3 - Neurogene Inc. (0001404644) (Issuer)
- SECNeurogene Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Neurogene Inc. (0001404644) (Filer)
- PRNeurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of DirectorsMs. Shafer, a proven commercial leader in rare neurological diseases, will lead Neurogene's commercial strategy and launch readiness for NGN-401 gene therapy for Rett syndrome Ms. Mikail, President and CFO of Neurogene, adds strategic and operational leadership to the Board as Company advances key priorities Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the appointment of Christy Shafer as Chief Commercial Officer and the appointment of Christine Mikail, J.D., to its Board of Directors. Ms. Shafer brings more than 20 years of industry experience buil
- SECSEC Form DEF 14A filed by Neurogene Inc.DEF 14A - Neurogene Inc. (0001404644) (Filer)
- SECSEC Form DEFA14A filed by Neurogene Inc.DEFA14A - Neurogene Inc. (0001404644) (Filer)
- PRNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 69,140 shares of the Company's common stock to four new employees (the "Inducement Grants") on April 6, 2026 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Lis
- INSIDERSEC Form 4 filed by Cvijic Christine Mikail4 - Neurogene Inc. (0001404644) (Issuer)
- INSIDERSEC Form 4 filed by Jordan Julie4 - Neurogene Inc. (0001404644) (Issuer)
- INSIDERSEC Form 4 filed by Mcminn Rachel4 - Neurogene Inc. (0001404644) (Issuer)
- SECSEC Form S-8 filed by Neurogene Inc.S-8 - Neurogene Inc. (0001404644) (Filer)
- SECSEC Form 10-K filed by Neurogene Inc.10-K - Neurogene Inc. (0001404644) (Filer)
- SECNeurogene Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Neurogene Inc. (0001404644) (Filer)
NGNE FAQ
6 questionsWhere does NGNE stock trade?
Neurogene Inc. (NGNE) is listed on NASDAQ.What sector and industry is NGNE in?
Neurogene Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Neurogene Inc. go public?
Neurogene Inc. (NGNE) completed its IPO in 2014.What are analysts saying about NGNE?
Neurogene Inc. has had 7 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy on 2026-06-03. Recent price targets range from $2400.00 to $4600.00.What companies are similar to NGNE?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NGNE side-by-side with any of them on Quantisnow.How can I track NGNE on Quantisnow?
Quantisnow aggregates Neurogene Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NGNE to receive live email and push alerts on every new disclosure.